Asston Pharmaceuticals Ltd

As of November 17, 2025, Asston Pharmaceu is fairly valued with a PE Ratio of 18.10, significantly lower than its expensive peers Sun Pharma and Divi's Lab, and has outperformed the Sensex with a 6.16% return over the past week.

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Asston Pharmaceu is scheduled to announce its results on 14 November 2025.

As of August 29, 2025, Asston Pharmaceu is considered very expensive and overvalued with a PE ratio of 19.46, significantly higher than its peers, and has underperformed against the Sensex, declining by 15.85% in the past month.

As of August 29, 2025, Asston Pharmaceu is considered very expensive and overvalued with a PE ratio of 19.46, significantly higher than its peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a 1-month return of -15.85%.